UN
Unichem Laboratories Ltd (UNICHEMLAB)
₹548.85
Mkt cap
₹3,842 Cr
P/E ratio
31.40
P/B
1.42
Div yield
0.00%
ROE
3.17%
ROCE
4.13%
EPS (TTM)
₹17.48
Book value
₹386
52W range
278–687
Sector
Healthcare
Price history
Previous close
Unichem Laboratories Ltd is involved in pharmaceuticals in Generics, APIs and Contract Manufacturing (CMO) areas. [1]
NSE UNICHEMLABBSE 506690
Health check
Mixed
ValuationFair
ProfitabilityWeak
GrowthModerate
TechnicalsBullish
52-week range
−20.13% from high₹549
₹278+97.29% from low₹687
Current
₹548.85
Prev close
₹531.20
Day
+3.32%
Price performance
1D
+3.32%
1W
+2.32%
1M
+0.16%
3M
+15.00%
6M
+83.99%
1Y
+14.61%
YTD
+24.23%
Financials
Revenue, profit & margin
P/E ratio
31.4×
UNICHEMLAB is 9% below the sector median of 34.6×
UNICHEMLAB31.4×
Sector median34.6×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 423 | 416 | 466 | 432 | 483 | 507 | 533 | 587 | 527 | 579 | 521 | 575 | 633 | |
| Expenses | 395 | 407 | 435 | 406 | 443 | 452 | 448 | 503 | 504 | 513 | 476 | 527 | 563 | |
| Operating Profit | 28 | 9 | 31 | 25 | 40 | 55 | 86 | 84 | 22 | 66 | 45 | 48 | 70 | |
| OPM % | 7% | 2.1% | 7% | 6% | 8% | 11% | 16% | 14% | 4.3% | 11% | 9% | 8% | 11% | |
| Other Income | 9 | 6 | 79 | -119 | 4 | 9 | 14 | 9 | 7 | -37 | 287 | 11 | 16 | |
| Interest | 6 | 7 | 6 | 5 | 4 | 5 | 7 | 5 | 7 | 8 | 7 | 9 | 7 | |
| Depreciation | 29 | 29 | 32 | 27 | 32 | 32 | 31 | 30 | 32 | 31 | 31 | 31 | 30 | |
| Profit before tax | 2 | -22 | 73 | -126 | 8 | 27 | 62 | 58 | -9 | -11 | 293 | 19 | 49 | |
| Tax % | 132% | 12% | -0% | 3% | 74% | 9% | 6% | 8% | 16% | 10% | 10% | 42% | 15% | |
| Net Profit | -1 | -24 | 73 | -129 | 2 | 25 | 58 | 53 | -10 | -12 | 264 | 11 | 41 | |
| EPS in Rs | -0.10 | -3.48 | 10.40 | -18.37 | 0.29 | 3.50 | 8.22 | 7.52 | -1.49 | -1.69 | 37.54 | 1.55 | 5.89 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +13.14% · closed higher next day 1 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 11 Aug '26 |
| Earnings day | +13.14% |
| +1 day | +7.45% |
| +5 days | +4.43% |
| +15 days | +9.70% |
| +30 days | +13.02% |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Jun 202670.22%Promoter
Promoters70.22%
FIIs0.90%0.10
DIIs10.46%0.17
Public18.41%0.27
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,837.30 | 34.90 | 4,40,830 | 0.87% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| Divi's Lab. | ₹9,375.00 | 83.54 | 2,48,877 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,840.00 | 82.51 | 1,84,098 | 0.79% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| Zydus Lifesci. | ₹1,160.00 | 23.77 | 1,15,710 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Cipla | ₹1,394.50 | 31.48 | 1,12,656 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Laurus Labs | ₹1,954.00 | 96.56 | 1,05,577 | 0.10% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| Aurobindo Pharma | ₹1,734.00 | 26.39 | 99,771 | 0.23% | 1,032 | +28.11% | 9,150 | +16.30% | 12.86% |
| Unichem Labs. | ₹545.70 | 31.43 | 3,842 | 0.00% | 41 | +496.08% | 633 | +20.13% | 4.13% |
| Median: 158 Co. | ₹433.90 | 34.56 | 2,205 | 0.08% | 13 | +29.57% | 164 | +18.57% | 14.96% |
Filings
Annual reports15
Concall transcripts11
Credit ratings6
Announcements5
Disclosure Under Regulation 30 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 19 Sep - Commissioner (Appeals) Thane disallowed Rs87.07 crore penalty and Rs6.59 crore interest; company will appeal.Extension Of The Exercise Period For The Options Granted And
Vested Under Unichem Employee Stock Option Scheme 2018 11 Sep - Unichem extended ESOP exercise period for 250,000 and 125,000 vested options to 31 March 2027.Significant Increase In The Volume Of Securities. 26 Aug - Unichem says share volume spike is market-driven and has no comment.Clarification sought from Unichem Laboratories Ltd 26 Aug - Exchange has sought clarification from Unichem Laboratories Ltd on August 26, 2026, with reference to Movement in Volume.Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 12 Aug - 63rd AGM held 11 Aug 2026; all five resolutions passed, including MD/CEO reappointment for three years.